Correction of Psoriatic T Cell Signatures by Deucravacitinib
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• 18 years of age or older
• Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)
Locations
United States
California
University of California, San Francisco
RECRUITING
San Francisco
Contact Information
Primary
Raymond Cho, MD, PhD
rashes@ucsf.edu
415 575 0524
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2026-06
Participants
Target number of participants: 25
Treatments
Experimental: deucravacitinib treatment
treatment with deucravacitinib for 6 months
Related Therapeutic Areas
Sponsors
Collaborators: Bristol-Myers Squibb
Leads: University of California, San Francisco